More than 260 European drug policy NGOs and 130 drug policy experts from 25 EU Member States have already signed the 2024 Manifesto for a progressive EU drug policy.
TEDI find consistent adulteration and risk trends across Europe's drug market since 2018, and call for more resources to improve market monitoring and harm reduction.
Stronger cooperation with civil society is essential to ensure the European Drugs Agency continues to prioritise health, social justice and human rights.
The EU Civil Society Forum on Drugs discusses decriminalisation, focusing on members' perspectives and noting how this framework could contribute to the EU's commitment to balanced, human-rights based approach.
EuroNPUD explore community-led communicable disease testing and care integration for people who use drugs, assessing best practice and attitudes surrounding these services.
Youth RISE, SSDP International and Young Wave present a sustainability framework to develop skills, knowledge, network and strategies for young people in drug-related organisations internationally.
The BOOST project seeks to combat HIV/AIDS and viral hepatitis in Europe through community-led harm reduction initiatives, aiming to enhance health services for people who use drugs and marginalised populations.
Over 30 European organisations acknowledge the failure of drug policies and demand a new approach prioritising health, rights, and community participation
EMCDDA and Europol raise concerns on the threats of highly potent synthetic substances and the need to invest in harm reduction approaches, as one of the policy options to address the drug situation in Europe.
The Eastern and Central European and Central Asian Commission on Drug Policy calls to attention the external and internal elements affecting the drug situation in the region, and highlights opportunities for effective and humane drug policy reform.
